Form 4: Quest Diagnostics SVP Boosts Stake via Performance Award

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, increased direct ownership of company common stock following a performance award settlement.

Summary

• Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics Inc. (DGX), acquired 6,200 shares of common stock on March 4, 2026, at a price of $204.86 per share.
• This acquisition was a settlement of a performance stock award approved in accordance with Rule 16b-3(d).
• Concurrently, Kuppusamy disposed of 2,628 shares of common stock at the same price to cover tax withholding obligations arising from the performance stock award settlement.
• Following these transactions, Kuppusamy directly owns 13,441 shares of Quest Diagnostics common stock.
• Total beneficial ownership, including shares held indirectly by a Trust (358 shares) and in a 401(k) plan (1,658 shares), amounts to 15,457 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as an executive received a performance award, indicating achievement of company goals and increasing their stake, even with the necessary tax-related sale.

Positives

• Karthik Kuppusamy, SVP, Clinical Solutions, received 6,200 shares of common stock as a performance award, indicating achievement of company goals.
• The net effect of the transactions is an increase in direct beneficial ownership by 3,572 shares (6,200 acquired 2,628 disposed for taxes).

Negatives

• No specific negative points are identified in this routine insider transaction filing.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Quest Diagnostics' future performance or strategic outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the settlement of performance awards and subsequent tax-related dispositions, are common across industries. These transactions typically reflect executive compensation structures rather than specific market or industry trends. While the acquisition of shares indicates continued executive alignment with shareholder interests, the scale of this transaction is not significant enough to signal broader industry shifts or competitive positioning.

Stakeholder Impact

• Shareholders: The executive's increased direct ownership (net of tax sales) aligns their interests further with shareholders.
• Employees: No direct impact on general employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing beyond the reported transactions.

Key Dates

Keywords

Quest Diagnostics, DGX, Karthik Kuppusamy, Form 4, Insider Transaction, Performance Award, Executive Compensation, Stock Ownership